BioXcel Therapeutics, Inc. (BTAI)

NASDAQ: BTAI · IEX Real-Time Price · USD
12.11
+0.05 (0.41%)
Jun 24, 2022 4:00 PM EDT - Market closed
0.41%
Market Cap 338.90M
Revenue (ttm) n/a
Net Income (ttm) -112.03M
Shares Out 27.99M
EPS (ttm) -4.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,182,269
Open 12.47
Previous Close 12.06
Day's Range 11.91 - 12.60
52-Week Range 8.80 - 36.49
Beta 1.30
Analysts Buy
Price Target 58.75 (+385.1%)
Earnings Date Aug 9, 2022

About BTAI

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutic... [Read more...]

Industry Biotechnology
IPO Date Mar 8, 2018
CEO Vimal Mehta
Employees 89
Stock Exchange NASDAQ
Ticker Symbol BTAI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for BTAI stock is "Buy." The 12-month stock price forecast is 58.75, which is an increase of 385.14% from the latest price.

Price Target
$58.75
(385.14% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

NEW HAVEN, Conn., June 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transf...

2 Stocks Under $20 That Could Double Your Money

These two companies have gotten quite the haircuts in recent months.

Other symbols: PLNHF

BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference

NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfo...

Why Shares of BioXcel Therapeutics Climbed 25.2% This Week

With the company's launch of its first marketed drug on the horizon, investors showed some excitement.

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights

Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults

Why BioXcel Therapeutics Shares Went Up 12.9% This Week

The company is stepping up its efforts to expand the label uses of its lead therapy.

BioXcel Therapeutics to Present at Three Upcoming Investor Conferences

NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfo...

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation i...

Top-line data for TRANQUILITY II anticipated in Q4 2022/early Q1 2023

2 Small-Cap Stocks With Monster Upsides, According to Wall Street

Sometimes analysts are on the spot, and other times, not so much.

Other symbols: OCGN

BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022

NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify...

BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology

OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority

Investment will support upcoming U.S. commercial launch activities of IGALMI™ and further clinical pipeline development

4 Top Stock Trades for Thursday: MSFT, TWTR, BTAI, PXD

Microsoft, Twitter, BioXcel Therapeutics and Pioneer Natural Resources were our top stock trades for Thursday. Here's the trade now.

Other symbols: MSFTTWTRPXD

Why BioXcel Therapeutics Stock Is Surging Today

BioXcel Therapeutics Inc (NASDAQ: BTAI) shares are trading higher Wednesday after the company announced that the U.S. Food and Drug Administration approved IGALMI (dexmedetomidine) sublingual film for t...

BioXcel says the FDA approved its therapy for adults with schizophrenia or bipolar disorder

Shares of BioXcel Therapeutics Inc. BTAI, -2.98% jumped 14.6% in premarket trading on Wednesday after the company said the Food and Drug Administration approved Igalmi, a sublingual film used to treat a...

BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agita...

First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar I or II disorder 1

Why Shares of BioXcel Therapeutics Shot Up 25.4% This Week

Investors may be anticipating a positive review by the FDA of the company's lead drug candidate.

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

Ready to launch BXCL501 upon approval as Company nears April 5, 2022 PDUFA action date

BioXcel Therapeutics to Present at the Barclays Global Healthcare Conference

NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfo...

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfor...

BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivot...

BXCL501 demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo

BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2...

BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts

BioXcel Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

NEW HAVEN, Conn., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfor...

BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer

NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfor...

BioXcel Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

NEW HAVEN, Conn., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfor...